Company Insights

AMRX customer relationships

Explore interactive graphBrowse insights index
AMRX customer relationship map

Amneal Pharmaceuticals (AMRX): The customer map that drives revenue — and the constraints investors must price in

Amneal operates as an integrated generic and specialty pharmaceutical company that manufactures, licenses, markets and distributes products through three commercial channels: major wholesalers and retail chains, institutional/government sales via its AvKARE distribution unit, and specialty collaborations/licensing with larger pharma partners. The company monetizes primarily by selling finished pharmaceuticals to a concentrated set of large buyers, while extracting incremental margin from specialty launches and partnerships. For a concise view of how these customer ties translate into revenue concentration and strategic exposure, see the company profile at NullExposure: https://nullexposure.com/.

How Amneal actually makes money (investor primer)

Amneal’s cash generation rests on two commercial realities. First, volume sales of branded and generic products to a small roster of large wholesalers and retail pharmacy chains supply the bulk of top-line revenue. Second, a distinct distribution business (AvKARE) sells into U.S. government agencies and institutional customers, creating a recurring contract-like revenue stream that sits alongside product sales. The company also pursues collaborations and specialty product launches (for example, commercializing CREXONT® and working with large pharma partners on GLP‑1 programs) that lift margins and diversify revenue beyond the commoditized generics channel. For a broader look at customer concentration and counterparty risk, visit NullExposure: https://nullexposure.com/.

Constraints and operating-model signals that matter for valuation

  • High concentration, high criticality. The 2024 Form 10‑K reports that Amneal’s four largest customers—Cencora, McKesson, Cardinal Health and CVS Health—accounted for roughly 70% of net sales in 2024, 2023 and 2022; that concentration is a structural constraint on pricing power and earnings stability.
  • Powerful counterparties and consolidation. The company sells into large enterprise wholesalers and retail chains that have consolidated alliances; this creates a contracting posture where Amneal negotiates with counterparty groups that command distribution scale and leverage.
  • Government channel maturity. AvKARE is explicitly focused on U.S. government agencies (Department of Defense and VA) and acts as a re‑packager and distributor; that provides predictable contract revenue but exposes Amneal to procurement rules and reimbursement dynamics.
  • Distribution-led segment dynamics. Amneal’s distribution capability is an operational asset but also a scale-dependent business that competes on contract terms and service levels. These constraints together define concentration risk, counterparty bargaining power, and a mixed maturity profile: mature distribution relationships coexisting with growth-stage specialty collaborations.

A line-by-line look at every named relationship in the filings and calls

Below are all relationships cited in Amneal’s customer scope results, with a one-to-two sentence summary and the filing or call that references them.

Cencora, Inc.

Cencora is listed in the 2024 Form 10‑K as one of Amneal’s four largest customers, forming part of the group that together accounted for approximately 70% of net sales in 2024. (Source: Amneal 2024 Form 10‑K, FY2024.)

CVS Caremark

CVS Caremark is noted in the 2024 10‑K as an example of a retailer/wholesaler alliance that shapes distribution negotiations and buyer concentration. (Source: Amneal 2024 Form 10‑K, FY2024.)

CVS Health Corporation

CVS Health is explicitly one of Amneal’s four largest customers that drove the company’s high revenue concentration in 2024. (Source: Amneal 2024 Form 10‑K, FY2024.)

McKesson Drug Co.

McKesson is named among the top four customers responsible for a material share of Amneal’s net revenue, underscoring the company’s exposure to major wholesalers. (Source: Amneal 2024 Form 10‑K, FY2024.)

Tourist Securities (earnings call participation)

Tourist Securities was logged as a questioner on the 2025 Q4 earnings call, representing sell‑side interest rather than a commercial buyer relationship. (Source: Amneal 2025 Q4 earnings call transcript, 2025Q4.)

McKesson Drug Company (second mention)

The 10‑K also references McKesson in an illustrative passage about alliances and consolidation among wholesalers and retailers that affect Amneal’s distribution environment. (Source: Amneal 2024 Form 10‑K, FY2024.)

Cardinal Health, Inc.

Cardinal Health is one of the four largest customers identified in the 2024 10‑K and therefore a material revenue counterparty for Amneal. (Source: Amneal 2024 Form 10‑K, FY2024.)

Walgreens

Walgreens is cited in the 10‑K as part of the industry’s alliance landscape (example pairing with Cencora), pointing to the consolidated buyer structure Amneal negotiates with. (Source: Amneal 2024 Form 10‑K, FY2024.)

Pfizer (Q4 2025 mention)

On the 2025 Q4 earnings call Amneal reported that its collaboration with Pfizer on GLP‑1 programs is progressing well, indicating active specialty workstreams with a major pharma partner. (Source: Amneal 2025 Q4 earnings call, 2025Q4.)

Piper Sandler (earnings call participation)

Piper Sandler participated in the 2025 Q4 earnings call as an analyst asking questions; this documents sell‑side engagement rather than a customer contract. (Source: Amneal 2025 Q4 earnings call, 2025Q4.)

Rite Aid

Rite Aid is referenced in the 10‑K as an example of a retail/wholesale alliance—part of the consolidated distribution base that drives Amneal’s commercial dynamics. (Source: Amneal 2024 Form 10‑K, FY2024.)

Novo (2025 Q3 earnings call)

On the 2025 Q3 earnings call Amneal referenced a competing bid by Novo for Metsera at a higher price, signaling market activity around assets tied to Amneal’s specialty programs. (Source: Amneal 2025 Q3 earnings call, 2025Q3.)

Pfizer (Q3 2025 mention)

During the 2025 Q3 call, analysts asked how Pfizer’s acquisition of Metsera could impact existing agreements, demonstrating that Amneal’s Pfizer collaboration is contractually relevant and monitored by investors. (Source: Amneal 2025 Q3 earnings call, 2025Q3.)

Goldman Sachs (earnings call participation)

Goldman Sachs participated in the 2025 Q4 earnings call, again documenting institutional investor/sell‑side scrutiny of Amneal’s commercial progress. (Source: Amneal 2025 Q4 earnings call, 2025Q4.)

JPMorgan (earnings call participation)

JPMorgan posed questions on the 2025 Q4 earnings call, underscoring continued analyst focus on revenue mix and customer exposure. (Source: Amneal 2025 Q4 earnings call, 2025Q4.)

AvKARE (GlobeNewswire FY2026 release)

GlobeNewswire releases for Amneal’s FY2025 and FY2026 results state that revenue, COGS and gross profit from sales of Amneal products by AvKARE were included in the Affordable Medicines segment, confirming AvKARE’s role as a revenue channel. (Source: Amneal press releases on GlobeNewswire, FY2026 and FY2025.)

AvKARE (GlobeNewswire FY2025 release — Oct 2025)

An October 2025 results release reiterates that AvKARE’s product sales are consolidated into the Affordable Medicines segment, highlighting the segment accounting and the government/institutional distribution role. (Source: Amneal press release on GlobeNewswire, Oct 30, 2025.)

Cardinal Health (SEC/10‑K entry, CAH ticker note)

Cardinal Health is also recorded with inferred ticker CAH in the Form 10‑K, reinforcing its identification as one of the material wholesalers in Amneal’s customer list. (Source: Amneal 2024 Form 10‑K, FY2024.)

AvKARE (GlobeNewswire FY2025 release — Aug 2025)

An August 2025 release again documents that AvKARE sales are included in the Affordable Medicines segment, making the distributor’s volumes visible in reported revenue lines. (Source: Amneal press release on GlobeNewswire, Aug 5, 2025.)

What this customer map means for investors

  • Concentration is the dominant risk factor. With four wholesalers accounting for roughly 70% of revenue, loss or price pressure from any single counterparty will move earnings materially, so model sensitivity to customer retention and margin compression is essential.
  • Counterparty bargaining power is structural. Consolidated wholesalers and retail alliances set terms that compress generic margins; specialty and collaboration revenues (e.g., Pfizer GLP‑1 work, CREXONT commercialization) are the paths to differentiated margin.
  • Government distribution is a stabilizer with policy exposure. AvKARE provides steady institutional channels, but contracting and reimbursement cycles create a different volatility profile than retail wholesalers.

If you want a reproducible, structured view of Amneal’s commercial ties and the filings that support them, explore the Amneal customer dossier at NullExposure: https://nullexposure.com/. For a tailored briefing or to map counterparty exposure across other healthcare names, visit https://nullexposure.com/ and request a custom analysis.

Bottom line: Amneal’s revenue engine is powerful but concentrated; investors should value growth from specialty launches and partnerships while pricing in the asymmetric downside of concentrated wholesale exposure.